Novel analogs of choline as potential neuroprotective agents

Jerry J. Buccafusco, J. Warren Beach, Alvin V. Terry, Gurbir S. Doad, Ajay Sood, Esperanza Arias, Hidemi Misawa, Manabu Masai, Takeshi Fujii, Koichiro Kawashima

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The ability of choline to serve as a full, though low potency agonist for the α7 nicotinic receptor has provided the impetus to develop analogs that exhibit levels of potency and effectiveness suitable for use as therapeutic agents. Seven analogs of choline were synthesized based on previous work with the analog pyrrolidinecholine. The drugs were administered to differentiated PC-12 cells 24 hr prior to growth factor withdrawal which itself induced cytotoxicity in 30-40% of the cells. Three of 7 choline analogs exhibited potency and efficacy similar to that for nicotine as cytoprotective agents. Despite being tertiary amines, 4 of the choline analogs were more potent than choline in inhibiting [3H]choline uptake into cultured fibroblasts transfected with the high affinity, sodium-dependent choline transporter. One of the most effective analogs JAY 2-21-29 was shown to produce a potent (EC50 ∼ 30 nM) cytoprotective action that was blocked by pretreatment with the α7 nicotinic receptor selective antagonist methyllycaconitine, but not by theα2 subtype-preferring antagonist dihydro-β-erythroidin. These preliminary studies support the further neurochemical characterization of these compounds 1) as selectiveα7 nicotinic receptor agonists and, 2) based on their interaction with the choline transporter, as potential cholinergic false neurotransmitters as has been demonstrated for pyrrolidinecholine.

Original languageEnglish
JournalJournal of Alzheimer's Disease
Volume6
Issue numberSUPPL.
Publication statusPublished - 2004
Externally publishedYes

Fingerprint

Neuroprotective Agents
Choline
Nicotinic Receptors
Nicotinic Agonists
Therapeutic Uses
Nicotine
Cholinergic Agents
Amines
Neurotransmitter Agents
Intercellular Signaling Peptides and Proteins
Fibroblasts
Sodium
Pharmaceutical Preparations

Keywords

  • Choline analog
  • Choline uptake
  • Cytoprotection
  • Nicotinic receptor
  • PC-12 cells
  • Structure-activity

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology

Cite this

Buccafusco, J. J., Beach, J. W., Terry, A. V., Doad, G. S., Sood, A., Arias, E., ... Kawashima, K. (2004). Novel analogs of choline as potential neuroprotective agents. Journal of Alzheimer's Disease, 6(SUPPL.).

Novel analogs of choline as potential neuroprotective agents. / Buccafusco, Jerry J.; Beach, J. Warren; Terry, Alvin V.; Doad, Gurbir S.; Sood, Ajay; Arias, Esperanza; Misawa, Hidemi; Masai, Manabu; Fujii, Takeshi; Kawashima, Koichiro.

In: Journal of Alzheimer's Disease, Vol. 6, No. SUPPL., 2004.

Research output: Contribution to journalArticle

Buccafusco, JJ, Beach, JW, Terry, AV, Doad, GS, Sood, A, Arias, E, Misawa, H, Masai, M, Fujii, T & Kawashima, K 2004, 'Novel analogs of choline as potential neuroprotective agents', Journal of Alzheimer's Disease, vol. 6, no. SUPPL..
Buccafusco JJ, Beach JW, Terry AV, Doad GS, Sood A, Arias E et al. Novel analogs of choline as potential neuroprotective agents. Journal of Alzheimer's Disease. 2004;6(SUPPL.).
Buccafusco, Jerry J. ; Beach, J. Warren ; Terry, Alvin V. ; Doad, Gurbir S. ; Sood, Ajay ; Arias, Esperanza ; Misawa, Hidemi ; Masai, Manabu ; Fujii, Takeshi ; Kawashima, Koichiro. / Novel analogs of choline as potential neuroprotective agents. In: Journal of Alzheimer's Disease. 2004 ; Vol. 6, No. SUPPL.
@article{124d640bb2d642748c0870ce178e3dc1,
title = "Novel analogs of choline as potential neuroprotective agents",
abstract = "The ability of choline to serve as a full, though low potency agonist for the α7 nicotinic receptor has provided the impetus to develop analogs that exhibit levels of potency and effectiveness suitable for use as therapeutic agents. Seven analogs of choline were synthesized based on previous work with the analog pyrrolidinecholine. The drugs were administered to differentiated PC-12 cells 24 hr prior to growth factor withdrawal which itself induced cytotoxicity in 30-40{\%} of the cells. Three of 7 choline analogs exhibited potency and efficacy similar to that for nicotine as cytoprotective agents. Despite being tertiary amines, 4 of the choline analogs were more potent than choline in inhibiting [3H]choline uptake into cultured fibroblasts transfected with the high affinity, sodium-dependent choline transporter. One of the most effective analogs JAY 2-21-29 was shown to produce a potent (EC50 ∼ 30 nM) cytoprotective action that was blocked by pretreatment with the α7 nicotinic receptor selective antagonist methyllycaconitine, but not by theα2 subtype-preferring antagonist dihydro-β-erythroidin. These preliminary studies support the further neurochemical characterization of these compounds 1) as selectiveα7 nicotinic receptor agonists and, 2) based on their interaction with the choline transporter, as potential cholinergic false neurotransmitters as has been demonstrated for pyrrolidinecholine.",
keywords = "Choline analog, Choline uptake, Cytoprotection, Nicotinic receptor, PC-12 cells, Structure-activity",
author = "Buccafusco, {Jerry J.} and Beach, {J. Warren} and Terry, {Alvin V.} and Doad, {Gurbir S.} and Ajay Sood and Esperanza Arias and Hidemi Misawa and Manabu Masai and Takeshi Fujii and Koichiro Kawashima",
year = "2004",
language = "English",
volume = "6",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "SUPPL.",

}

TY - JOUR

T1 - Novel analogs of choline as potential neuroprotective agents

AU - Buccafusco, Jerry J.

AU - Beach, J. Warren

AU - Terry, Alvin V.

AU - Doad, Gurbir S.

AU - Sood, Ajay

AU - Arias, Esperanza

AU - Misawa, Hidemi

AU - Masai, Manabu

AU - Fujii, Takeshi

AU - Kawashima, Koichiro

PY - 2004

Y1 - 2004

N2 - The ability of choline to serve as a full, though low potency agonist for the α7 nicotinic receptor has provided the impetus to develop analogs that exhibit levels of potency and effectiveness suitable for use as therapeutic agents. Seven analogs of choline were synthesized based on previous work with the analog pyrrolidinecholine. The drugs were administered to differentiated PC-12 cells 24 hr prior to growth factor withdrawal which itself induced cytotoxicity in 30-40% of the cells. Three of 7 choline analogs exhibited potency and efficacy similar to that for nicotine as cytoprotective agents. Despite being tertiary amines, 4 of the choline analogs were more potent than choline in inhibiting [3H]choline uptake into cultured fibroblasts transfected with the high affinity, sodium-dependent choline transporter. One of the most effective analogs JAY 2-21-29 was shown to produce a potent (EC50 ∼ 30 nM) cytoprotective action that was blocked by pretreatment with the α7 nicotinic receptor selective antagonist methyllycaconitine, but not by theα2 subtype-preferring antagonist dihydro-β-erythroidin. These preliminary studies support the further neurochemical characterization of these compounds 1) as selectiveα7 nicotinic receptor agonists and, 2) based on their interaction with the choline transporter, as potential cholinergic false neurotransmitters as has been demonstrated for pyrrolidinecholine.

AB - The ability of choline to serve as a full, though low potency agonist for the α7 nicotinic receptor has provided the impetus to develop analogs that exhibit levels of potency and effectiveness suitable for use as therapeutic agents. Seven analogs of choline were synthesized based on previous work with the analog pyrrolidinecholine. The drugs were administered to differentiated PC-12 cells 24 hr prior to growth factor withdrawal which itself induced cytotoxicity in 30-40% of the cells. Three of 7 choline analogs exhibited potency and efficacy similar to that for nicotine as cytoprotective agents. Despite being tertiary amines, 4 of the choline analogs were more potent than choline in inhibiting [3H]choline uptake into cultured fibroblasts transfected with the high affinity, sodium-dependent choline transporter. One of the most effective analogs JAY 2-21-29 was shown to produce a potent (EC50 ∼ 30 nM) cytoprotective action that was blocked by pretreatment with the α7 nicotinic receptor selective antagonist methyllycaconitine, but not by theα2 subtype-preferring antagonist dihydro-β-erythroidin. These preliminary studies support the further neurochemical characterization of these compounds 1) as selectiveα7 nicotinic receptor agonists and, 2) based on their interaction with the choline transporter, as potential cholinergic false neurotransmitters as has been demonstrated for pyrrolidinecholine.

KW - Choline analog

KW - Choline uptake

KW - Cytoprotection

KW - Nicotinic receptor

KW - PC-12 cells

KW - Structure-activity

UR - http://www.scopus.com/inward/record.url?scp=20844436602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20844436602&partnerID=8YFLogxK

M3 - Article

VL - 6

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - SUPPL.

ER -